临床医生对前列腺癌患者通用种系基因检测结果的管理建议报告
PROCLAIM试验对982例未选择的前列腺癌患者行种系基因检测,100例(10%)阳性、482例(49%)意义不确定、400例(41%)阴性。阳性患者较阴性或不确定患者更常获得治疗改变、随访改变和级联检测建议。不确定性结果也导致高于预期的管理改变,提示需加强临床医生遗传学教育。
要点
- 982例前列腺癌患者中10%种系阳性、49%意义不确定、41%阴性。
- 阳性患者获治疗改变建议18% vs 阴性或不确定1.4%(P < .001)。
- 阳性患者获随访改变64% vs 11%、级联检测71% vs 5.4%(P < .001)。
核心结论
- 种系基因检测结果影响前列腺癌患者的临床建议,尤其是阳性结果患者。
- 不确定结果患者出现高于预期的临床管理改变,提示需加强临床医生遗传学教育。
研究设计与样本
- PROCLAIM试验收集未选择的前列腺癌患者数据及临床医生建议。
- 共982例患者接受种系基因检测。
- 组间差异采用双侧Fisher精确检验,显著性设为P < .05。
- 采用逻辑回归评估检测结果对临床决策的影响,并控制诊断时间(新诊断 vs 既往诊断)。
主要发现
- 982例中100例(10%)阳性(≥1个致病性种系变异),482例(49%)结果不确定(≥1个意义不确定变异),400例(41%)阴性。
- 阳性患者较阴性或不确定患者更常获得治疗改变建议:18% vs 1.4%(P < .001)。
- 阳性患者较阴性或不确定患者更常获得随访改变建议:64% vs 11%(P < .001)。
- 阳性患者较阴性或不确定患者更常获得级联检测建议:71% vs 5.4%(P < .001)。
- 逻辑回归显示,控制新诊断或既往诊断后,阳性与不确定结果均与治疗改变和随访改变显著相关(P < .001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Identification of pathogenic germline variants in patients with prostate cancer can help inform treatment selection, screening for secondary malignancies, and cascade testing. Limited real-world data are available on clinician recommendations following germline genetic testing in patients with prostate cancer. MATERIALS AND METHODS: Patient data and clinician recommendations were collected from unselected patients with prostate cancer who underwent germline testing through the PROCLAIM trial. Differences among groups of patients were determined by 2-tailed Fisher's exact test with significance set at P < .05. Logistic regression was performed to assess the influence of test results in clinical decision-making while controlling for time of diagnosis (newly vs previously diagnosed). RESULTS: Among 982 patients, 100 (10%) were positive (≥1 pathogenic germline variant), 482 (49%) had uncertain results (≥1 variant of uncertain significance), and 400 (41%) were negative. Patients with positive results were significantly more likely than those with negative or uncertain results to receive recommendations for treatment changes (18% vs 1.4%, P < .001), follow-up changes (64% vs 11%, P < .001), and cascade testing (71% vs 5.4%, P < .001). Logistic regression demonstrated that positive and uncertain results were significantly associated with both changes to treatment and follow-up (P < .001) when controlling for new or previous diagnosis. CONCLUSIONS: Germline genetic testing results informed clinical recommendations for patients with prostate cancer, especially in patients with positive results. Higher than anticipated rates of clinical management changes in patients with uncertain results highlight the need for increased genetic education of clinicians treating patients with prostate cancer.
引用
- Shore N, Pieczonka C, Heron S, et al. Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer. J Urol. 2024. PMID: 39121056. doi:10.1097/JU.0000000000004190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。